It targets quickly dividing red blood cells to slow their production. A long-acting version, called peginterferon alfa (Pegasys), has fewer side effects. Ropeginterferon alfa-2b-njft (Besremi ...
Rubius Therapeutics is biologically engineering red blood cells to ... However, current CAR T cell treatments have shown limited efficacy with severe side effects and overall limited applicability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback